Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The First US Gene Therapy Maker Innovates On Pricing And Reimbursement

Executive Summary

Spark priced the gene therapy Luxturna for inherited blindness at $850,000 for treatment of both eyes, below the $1m price some expected, and revealed pioneering market access plans. CEO Jeffrey Marrazzo and Harvard Pilgrim's Michael Sherman talked with Scrip about the details.


Related Content

Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race
BioMarin CEO Suggests Hemophilia Gene Therapy Pricing In $2m-$3m Range
The Gene Therapies Are Coming – And So Are New Ways To Pay For Them
Amicus Makes Its Gene Therapy Move, Focusing On CNS Lysosomal Storage Disorders
Pfizer Advances Duchenne Drug As It Prioritizes Gene Therapy
Pharma Justifies Steep Prices, Plans Fancy Footwork In The Era Of Cures
Installment Payments For Gene Therapy; From Luxturna To Hemophilia
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Spark Stands By $1M Or More Price Possibility For Luxturna


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts